[{"id":"c8aaef7c-6714-47f7-9635-9d89ae988ee2","acronym":"LIBRA","url":"https://clinicaltrials.gov/study/NCT06982924","created_at":"2025-09-07T01:40:22.807Z","updated_at":"2025-09-07T01:40:22.807Z","phase":"Phase 2","brief_title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","source_id_and_acronym":"NCT06982924 - LIBRA","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • limertinib (ASK120067)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-05-21"}]